Literature DB >> 6520069

Diagnosis and epidemiology of Clostridium difficile enterocolitis in Sweden.

B Aronsson, R Möllby, C E Nord.   

Abstract

Experience of the diagnosis and epidemiology of Clostridium difficile in Sweden is reviewed. Samples from 5885 patients have been investigated at the National Bacteriological Laboratory in Stockholm from 1978-1983. Patients originate from all parts of the country and their number continues to increase. Cl. difficile seem to be of growing importance, especially in nosocomial infections. Most patients with antibiotic-associated diarrhoea and colitis (AAD/AAC) and Cl. difficile in their stools were above 60 years of age (63%) and there was a significant preponderance of females over males in the age groups 21-50 and above 60 years of age. The antibiotics most commonly associated with Cl. difficile enterocolitis (CDE) were penicillins, cephalosporins and clindamycin/lincomycin. On the basis of consumption clindamycin/lincomycin and cephalosporins are associated 70 and 40 times, respectively, more often than penicillins in CDE. Diagnosis of CDE relies mainly on detection of the cytotoxin (toxin B) in stool specimens. It was present in 873/4793 (18.2%) patients whereas the bacterium was found in only 12%. An immunoassay for detection of the enterotoxin (toxin A) of Cl. difficile seems to be a useful alternative to the cytotoxin assay, but some stool specimens with a low toxin B titre were negative. Five specimens negative for toxin B were positive for toxin A and came from patients where additional information suggested CDE. A serological assay for demonstration of circulating antibodies to Cl. difficile toxins has also been evaluated and is positive in about half of the cases of CDE. Antibody response seems to be absent or delayed in patients with relapse of colitis after antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6520069     DOI: 10.1093/jac/14.suppl_d.85

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Clostridium difficile: a pathogen of the nineties.

Authors:  T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

2.  Incidence and significance of Clostridium difficile in hospitalized cancer patients.

Authors:  M Gérard; N Defresne; D Daneau; P Van der Auwera; M Delmée; A M Bourguignon; F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

3.  Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery.

Authors:  G Privitera; P Scarpellini; G Ortisi; G Nicastro; R Nicolin; F de Lalla
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD Prevalence Surveillance Project.

Authors:  M Hyland; M Ofner-Agostini; M Miller; S Paton; M Gourdeau; M Ishak
Journal:  Can J Infect Dis       Date:  2001-03

5.  Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.

Authors:  M Ritz; H Lode; M Fassbender; K Borner; P Koeppe; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

6.  Monospecific antibodies for detection of Clostridium difficile enterotoxin.

Authors:  P Rautenberg; F Stender; U Ullmann
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

Review 7.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 8.  Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.

Authors:  Masako Mizusawa; Shira Doron; Sherwood Gorbach
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

Review 9.  Epidemiological aspects of infections caused by Bacteroides fragilis and Clostridium difficile.

Authors:  S Tabaqchali; M Wilks
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

10.  Treatment of Clostridium difficile-associated disease with teicoplanin.

Authors:  F de Lalla; G Privitera; E Rinaldi; G Ortisi; D Santoro; G Rizzardini
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.